Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update b

GUIDELINE TITLE
Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America.

BIBLIOGRAPHIC SOURCE(S)
Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America [published erratum: Clin Infect Dis 2010 Feb 1;50:457]. Clin Infect Dis 2009 Jul 1;49(1):1-45. [281 references] PubMed

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates previous versions: Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001 May 1;32(9):1249-72. [210 references]

Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE. Guidelines for the management of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2001 Apr;22(4):222-42. [210 references]

Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE. Guidelines for the management of intravascular catheter-related infections. J Intraven Nurs 2001 Jun;24(3):180-205. [210 references]

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

April 14, 2009 - Rocephin (ceftriaxone sodium): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of an update to a previous alert that addresses the interaction of ceftriaxone with calcium-containing products, based on previously reported fatal cases in neonates. Based on the results from recent in vitro studies, FDA now recommends that ceftriaxone and calcium-containing products may be used concomitantly in patients >28 days of age, using the precautionary recommendations noted because the risk of precipitation is low in this population. FDA had previously recommended, but no longer recommends, that in all age groups ceftriaxone and calcium-containing products should not be administered within 48 hours of one another.

abrir aquí para acceder al documento NGC AHRQ completo:
Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update b